Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany

Siedler, Anette; Dettmann, Marleen

doi:10.4161/hv.34426

Cited by 42 publications

(43 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have also shown that vaccination is associated with a significant decrease in varicella-related hospitalization rates (Table 3; ranging from 23% to 93% over a 4–14-year time period) [6,37,60,61,64–69]. The highest reductions were observed in individuals below 15 years old [6,37,60,61,65–67] and specifically in the youngest children [38,62,69].…”

Section: Evidence For Varicella Vaccinationmentioning

confidence: 99%

Varicella vaccination - the global experience

Wutzler

Bonanni

Burgess

et al. 2017

Expert Review of Vaccines

143

View full text Add to dashboard Cite

Introduction Varicella, although a frequently benign childhood disease, nevertheless represents a considerable health burden. WHO recommends including varicella vaccines in universal routine vaccination programs, and maintaining coverage >80%. Many countries have successfully introduced varicella vaccination and have benefited from lower disease burden, but many others have not adopted the vaccine. Reasons include cost commitment for a ‘mild childhood disease’ or concerns that vaccination will shift varicella to older age groups or increase herpes zoster incidence. Areas covered This literature review summarizes the effectiveness and epidemiological impact of varicella immunization programs. Expert commentary Varicella vaccines are immunogenic with acceptable safety profiles. One and two dose schedules are highly effective against varicella and large reductions in disease incidence, particularly moderate-severe disease, have been widely reported. There is currently no evidence to suggest that the introduction of varicella vaccination results in a shift of varicella disease burden to older age groups. Although epidemiological studies have shown an increased incidence of herpes zoster since the vaccines were launched, there are many other contributing factors, and indeed, this secular trend was evident before their introduction. In conclusion, varicella vaccination easily fits into existing immunization programs and significantly reduces the often underestimated burden of varicella.

show abstract

Section: Evidence For Varicella Vaccinationmentioning

confidence: 99%

Varicella vaccination - the global experience

Wutzler

Bonanni

Burgess

et al. 2017

Expert Review of Vaccines

143

View full text Add to dashboard Cite

show abstract

“…The incidence is higher among women than among men, and rises continuously from around the age of 50 years [28][29][30]. Based on statutory health insurance (SHI) data, the age-specific incidence of HZ ranges from 4 cases per 1,000 person-years (PY) among persons under the age of 50 to 14 cases per 1,000 PY among 80-89-year-olds [29].…”

Section: Epidemiologymentioning

confidence: 99%

“…Evaluations of hospitalization data also demonstrate a rise with increasing age from approx. 6.7/100,000 inhabitants between 20 and 49 years of age to 57.7/100,000 inhabitants 70 years of age and older (average of years 1995 to 2012; [30]). These data also show a continuous rise in age-adjusted hospitalizations from 9/100,000 inhabitants in 1995 to 17/100,000 in 2012.…”

Section: Epidemiologymentioning

confidence: 99%

“…PHN was selected as the secondary endpoint. PHN was defined as pain caused by HZ with a score of ≥3 on the pain scale, and which occurred or continued over certain periods of time (30,60,90, 120 and 182 days) after the initial occurrence of the HZ rash. The follow-up for PHN was limited to 182 days after the start of the rash.…”

Section: Shingles Prevention Study (Sps)mentioning

confidence: 99%

See 1 more Smart Citation

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…59 In conclusion, evidence of an increase of HZ in countries with a universal varicella vaccination program is not consistent; 60 many studies have shown evidence of increasing incidence trends in HZ in countries with or without a universal varicella vaccination program. 61,62,63 Besides, in some countries, HZ incidence started to increase years before the vaccine was introduced. For these reasons, continuous monitoring is needed to understand the secular trends in HZ before and after introduction of varicella vaccination programmes.…”

Section: Can Zoster Vaccine Be Co-administered To Other Vaccines?mentioning

confidence: 99%

Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience

Gabutti

Bonanni

Conversano³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Herpes zoster (HZ) is an acute viral illness characterized by a vesicular rash with unilateral distribution, which can also result in severe complications such as post-herpetic neuralgia (PHN), ophthalmic zoster, stroke or other neurological complications. The estimate incidence in Europe ranges between 2.0 and 4.6 cases per 1,000 person-years, with a sharp increase in >50 year-old subjects. Currently, treatment options for HZ are only partially effective in limiting the acute phase, while the management of complications is complex and often unsatisfactory. The total burden of the disease and the high costs related to its diagnostic and therapeutic management led researchers to develop a new preventive approach through a live attenuated virus vaccine. The currently available vaccine, with a high antigen content, is safe, well tolerated and reduces the incidence of HZ, PHN and the burden of illness. Several countries have introduced this vaccination, albeit with different recommendations and methods of financing. Taking into account the barriers to this immunization registered in some areas (difficulty of vaccine distribution, lack of physician recommendations, the cost of vaccine for patients, etc.), this group of Italian experts advocate that a common strategy able to guarantee a good compliance with this vaccination should be implemented. The same group addresses some practical questions concerning the use of zoster vaccine.

show abstract

Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany

Cited by 42 publications

References 18 publications

Varicella vaccination - the global experience

Varicella vaccination - the global experience

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience

Contact Info

Product

Resources

About